The European Commission and United States Food and Drug Administration (FDA) have both recently given the green light to market a new drug designed for adult patients with Cushing’s disease. This autoimmune disorder, which impacts roughly 13 million people per year, is a form of Cushing’s syndrome caused by a benign tumor on the pituitary gland. The tumor causes increased cortisol levels, and the goal of the drug is to lower cortisol levels without the unintended side effects seen with other medications such as hyperglycemia or liver damage.